+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 154 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.

Age: 18Years - 80YearsAll GendersPhase 3
109 locations
S

Actively Recruiting

Healthy Volunteer

This trial investigates ATI-1013, a drug being studied in healthy adult cigarette smokers to understand its safety, how long it stays in the body, whether it causes an immune response, and its effects on nicotine levels. The study compares ATI-1013 to a placebo to evaluate safety and how the drug interacts with nicotine. It is a first-in-human, phase 1 clinical trial conducted by Antidote Therapeutics, Inc. Participants receive one intravenous infusion of ATI-1013 at one of three escalating doses 0.2 g, 0.8 g, or 3.2 g or a placebo. The study uses a randomized, double-blind design with a 41 ratio favoring ATI-1013 in each dose group. The trial includes a screening period, a dosing day with at least 48 hours of in-clinic observation, and follow-up visits on Days 7, 21, 42, 56, and 84, plus telephone check-ins on Days 5, 14, 28, and 70. Participants keep a diary of their cigarette use and smoking habits. Researchers monitor adverse events, immune responses, and drug levels in the blood over 84 days. They also track nicotine-related physiological responses such as skin temperature, heart rate, blood pressure, and withdrawal symptoms, along with subjective effects of nicotine. Safety and drug behavior in the body are key outcomes throughout the study period.

Age: 23Years - 59YearsAll GendersPhase 1
1 location
L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of intermittent use of elismetrep for treating acute migraine attacks. This Phase 3 study compares two doses of elismetrep, 10 mg and 20 mg, to understand their safety profiles over an average of one year. The study involves adult participants who have previously used elismetrep in an acute treatment trial and met compliance requirements. Participants are randomly assigned to receive either 10 mg or 20 mg of elismetrep taken orally during migraine attacks. The study uses a triple-masked design to ensure unbiased results. The treatment period spans approximately one year, during which safety and adverse events are closely monitored. This includes tracking any adverse events leading to discontinuation or serious adverse events related to the study drug. During the study, participants will complete electronic diaries to record migraine episodes and medication use. They will also attend scheduled visits to assess safety and tolerability, including monitoring for adverse events. The research team will measure the proportion of participants experiencing treatment-emergent adverse events and serious adverse events through study completion. Participants are expected to use a personal smartphone to maintain study diaries and comply with study procedures throughout the study duration.

Age: 18Years +All GendersPhase 3
113 locations
S

Actively Recruiting

This trial studies adults aged 50 to under 80 with mild or moderate calcific aortic valve stenosis and elevated lipoproteina levels. Researchers are assessing the safety, tolerability, and ability of pelacarsen TQJ230 given once monthly by injection to slow the progression of this heart valve condition. The study compares pelacarsen to a placebo in a randomized, double-blind design. Participants receive either pelacarsen 80 mg or a matching placebo as a subcutaneous injection monthly. They continue treatment and monitoring for up to 36 months to observe changes in heart valve narrowing and calcium buildup. The study also tracks lipoproteina levels and clinical heart-related events during this period. Throughout the study, participants will have regular assessments including imaging to measure aortic valve function and calcium score, blood tests for lipoproteina, and monitoring for safety. The main outcomes analyzed after 36 months include changes in valve jet velocity and calcium score, alongside clinical events. Participants remain under medical care while being observed for any effects of the study drug or placebo.

Age: 50Years - 80YearsAll GendersPhase 2
140 locations
S

Actively Recruiting

Researchers are evaluating a new treatment approach for adults aged 18 to 75 years with newly diagnosed acute myeloid leukemia AML that has specific genetic changes in the NPM1, MLLKMT2A, or NUP98 genes. This phase Ib trial aims to find the best dose and assess the safety of the drug revumenib SNDX-5613 when combined with standard chemotherapy drugs daunorubicin and cytarabine. The study focuses on patients who can tolerate intensive chemotherapy and have untreated AML. Participants receive revumenib orally twice daily alongside daunorubicin given intravenously for 1 to 3 days and cytarabine given as a continuous infusion or intermittent intravenous infusion depending on the treatment phase. Treatment includes an induction phase, possible re-induction for persistent disease, and consolidation cycles repeated every 42 days up to three times if tolerated. During treatment, patients undergo heart function scans, bone marrow biopsies, and blood tests at scheduled times to monitor response and safety. Throughout the study, patients are closely monitored through clinical assessments, including pharmacokinetic studies of revumenib and evaluations of leukemia cell response. After completing treatment, participants are followed for up to two years or until relapse or death. Researchers measure the recommended dose for further study, complete response rates, and other important outcomes such as measurable residual disease and potential biomarkers related to treatment response.

Age: 18Years - 75YearsAll GendersPhase 1
23 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of intravenously administered YN001 in adults diagnosed with coronary atherosclerosis who are also receiving treatment for cardiovascular risk factors. This multinational, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial aims to compare different doses of YN001 with placebo in this population. Participants will be randomly assigned to receive one of three weekly intravenous treatments YN001 at 40mg, YN001 at 20mg, or a placebo at 0mg. Treatment will be administered once weekly for 13 weeks, totaling 13 doses. The study includes a screeningbaseline period lasting up to 12 weeks, a 12-week blinded treatment phase, followed by a 30-day safety follow-up and a long-term monitoring period lasting approximately 2 years after randomization. During the study, participants will undergo various assessments including imaging scans to measure changes in coronary and carotid artery plaque, blood tests to analyze YN001 concentration and immune responses, and monitoring for major adverse cardiac events. The primary measurement is the relative change in coronary non-calcified plaque volume from baseline to week 13. Safety and immune response will be closely tracked throughout treatment and follow-up, with total participation lasting up to about 2 years.

Age: 18Years - 80YearsAll GendersPhase 2
56 locations
R

Actively Recruiting

Researchers are evaluating treatments for patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms MPNs. This phase II trial compares ASTX727, a combination of cedazuridine and decitabine, given alone or combined with iadademstat. The study aims to assess how these treatments affect leukemia response rates and survival outcomes in patients who have not previously received certain DNA methyltransferase inhibitors. Patients are assigned to one of two groups. One group receives ASTX727 orally once daily on days 1 to 5 of each 28-day cycle. The other group receives the same ASTX727 schedule plus iadademstat orally on days 1-5, 8-12, 15-19, and 22-26 of each cycle. Treatment continues until disease progression or unacceptable side effects occur. Throughout the trial, researchers collect blood, buccal swab, and bone marrow samples to study the disease and treatment effects. Participants have regular assessments including blood tests, bone marrow biopsies, and sample collections over the treatment period. After stopping treatment for reasons other than disease progression, they are followed every 3 months if they stop due to progression, follow-up occurs every 6 months. The main outcome measured is the acute leukemia response rate within 4 treatment cycles. Secondary outcomes include event-free survival, overall survival, and the rate of stem cell transplantation over two years.

Age: 18Years +All GendersPhase 2
32 locations
S

Actively Recruiting

Researchers are studying the safety and effectiveness of UBT251 for people living with overweight or obesity. This clinical trial is a phase 2 study that compares different doses of UBT251 against a placebo, which contains no active medicine. The goal is to understand how UBT251 affects body weight and tolerability in adults with these conditions. Participants will be randomly assigned to receive various doses of UBT251 or a placebo, all given as injections under the skin of the abdomen. The study includes multiple parts where participants receive different dose levels, with some receiving a single dose and others multiple doses. Placebo injections are designed to look like UBT251 to maintain study blinding. During the trial, participants will be monitored for treatment-emergent adverse events and changes in body weight over several weeks. Blood samples will be taken to measure UBT251 levels in the body. The study involves regular visits for assessments including physical exams, vital signs, and lab tests, extending up to 33 weeks. Researchers will track safety, tolerability, and how the drug moves through the body to evaluate outcomes.

Age: 18Years - 65YearsAll GendersPhase 2
3 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and effectiveness of the FDA-approved VARIPULSE catheter system for pulmonary vein isolation PVI in treating people with symptomatic paroxysmal atrial fibrillation PAF. This study focuses on participants who are candidates for catheter ablation due to symptoms and have not responded well to certain antiarrhythmic drugs. Participants will undergo electrophysiology mapping and pulsed field ablation PFA using the VARIPULSE catheter combined with the TRUPULSE generator. This treatment is designed to isolate pulmonary veins to manage atrial fibrillation symptoms. The study observes outcomes both shortly after the procedure and over the long term. During the study, participants will be monitored for early adverse events within 7 days after the ablation procedure. They will also be followed for freedom from documented atrial tachyarrhythmia episodes from about 2 months up to 3 years after treatment. Assessments include clinical evaluations and adherence to follow-up testing to understand the devices safety and effectiveness over time.

Age: 22Years +All GendersPhase Not Applicable
25 locations
C

Actively Recruiting

Researchers are evaluating the combination of pembrolizumab and sacituzumab govitecan-hziy compared to standard chemotherapy treatments for patients with advanced urothelial cancer that has spread locally or to other parts of the body. This phase III trial aims to compare survival rates and other treatment responses between the new combination therapy and the usual care involving drugs like carboplatin, cisplatin, gemcitabine, docetaxel, or paclitaxel. The study also examines quality of life and side effects for both approaches. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy treatments such as carboplatin or cisplatin with gemcitabine, or alternatively docetaxel or paclitaxel, given intravenously in cycles every 21 days for up to six cycles if tolerated. The other group receives pembrolizumab intravenously on day 1 and sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle, continuing for up to 35 cycles or two years of pembrolizumab if there is no disease progression or unacceptable side effects. Throughout treatment, participants undergo blood tests and imaging scans like CT or MRI. Participants are followed closely during treatment with regular assessments including imaging and blood sample collection to monitor response and side effects. After treatment ends, follow-up visits occur at 30 days and then annually for five years to track overall survival and other health outcomes. The trial measures overall survival as the primary outcome and also evaluates progression-free survival, response rates, duration of response, adverse events, and quality of life aspects related to fatigue and bladder symptoms.

Age: 18Years +All GendersPhase 3
163 locations

1-10 of 154

1